Aligos Therapeutics, Inc. (ALGS) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Aligos Therapeutics reported revenue of $2.2M, down 39.5% from $3.6M the year before. Net income was -$24.2M (a -1106.7% net margin), or -$2.45 per diluted share. Operating margin was -4024.9%. Operating activities generated -$82.5M of cash. At fiscal year end, Aligos Therapeutics held $88.5M in total assets against $35.0M in total liabilities, including $18.3M of cash and equivalents.
Open the full interactive Aligos Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Aligos Therapeutics Key Stats
| Share Price | $5.51 |
|---|---|
| Market Cap | $57.5M |
| Revenue YoY Growth | -39.5% |
| 52-Week Range | $4.08 – $13.30 |
| Shares Outstanding | 10.4 million (basic, 2026 Q2) |
Aligos Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $6.2M | $3.6M | $2.2M |
| Operating Income | -$97.8M | -$128.3M | -$97.6M | -$88.1M | -$89.2M | -$88.0M |
| Pre-Tax Income | -$108.4M | -$128.2M | -$95.9M | -$86.9M | -$130.9M | -$23.9M |
| Income Tax | $161,000 | $143,000 | $106,000 | $795,000 | $331,000 | $314,000 |
| Net Income | -$108.5M | -$128.3M | -$96.0M | -$87.7M | -$131.2M | -$24.2M |
| Diluted EPS | -$271.75 | -$80.50 | -$56.25 | -$34.00 | -$20.94 | -$2.45 |
Aligos Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $741,000 | $169,000 | $2.8M | $0 |
| Net Income | -$31.5M | -$19.9M | -$23.0M | -$1.5M |
| Diluted EPS | -$3.04 | -$2.01 | -$2.21 | -$0.14 |
Aligos Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $220.4M | $186.8M | $81.3M | $135.7M | $37.0M | $18.3M |
| Current Assets | $250.0M | $204.4M | $133.5M | $141.1M | $62.1M | $82.9M |
| Total Assets | $265.3M | $235.4M | $146.7M | $151.5M | $70.1M | $88.5M |
| Current Liabilities | $30.3M | $39.0M | $33.1M | $23.9M | $21.7M | $21.2M |
| Total Liabilities | $45.3M | $50.6M | $42.8M | $59.4M | $99.1M | $35.0M |
| Shareholders' Equity | $220.0M | $184.7M | $103.9M | $92.1M | -$29.0M | $53.5M |
Aligos Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$74.3M | -$115.7M | -$79.4M | -$79.0M | -$80.7M | -$82.5M |
| Cash From Investing | $32.8M | $3.0M | -$26.3M | $45.0M | -$18.3M | -$37.8M |
| Cash From Financing | $192.3M | $78.7M | $164,000 | $88.3M | $355,000 | $101.6M |
| Free Cash Flow | -$76.3M | -$116.6M | -$80.3M | -$79.0M | -$80.9M | — |
Figures from Aligos Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Aligos Therapeutics financials page for every line item.
Aligos Therapeutics Company Profile
| Ticker | ALGS |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | South San Francisco, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001799448 |
Frequently Asked Questions
What was Aligos Therapeutics' revenue in fiscal 2025?
Aligos Therapeutics (ALGS) reported revenue of $2.2M for fiscal 2025.
What is Aligos Therapeutics' annual revenue history?
Aligos Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $6.2M; 2024: $3.6M; 2025: $2.2M.
What was Aligos Therapeutics' net income in fiscal 2025?
Aligos Therapeutics reported net income of -$24.2M for fiscal 2025.
What was Aligos Therapeutics' earnings per share (EPS) in fiscal 2025?
Aligos Therapeutics' diluted EPS was -$2.45 for fiscal 2025 (adjusted for any later stock splits).
What was Aligos Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Aligos Therapeutics reported revenue of $0.
How many shares of Aligos Therapeutics are outstanding?
Aligos Therapeutics reported a weighted average of 10.4 million basic shares outstanding in 2026 Q2.
What is Aligos Therapeutics' market cap?
Based on its latest closing price, Aligos Therapeutics (ALGS) has a market capitalization of about $57.5M.
When does Aligos Therapeutics' fiscal year end?
Aligos Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Aligos Therapeutics headquartered?
Aligos Therapeutics lists its business address in South San Francisco, California in its SEC filings.
Aligos Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →